Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAE609 (Cipargamin) in Uncomplicated Malaria
NCT01524341Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2012
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cipargamin in Plasmodium falciparum malaria, malaria, sponsored by Novartis. Started Jan 2012; status: completed.
02
Drugs
cipargamin
03
Conditions
Plasmodium falciparum malariamalaria
Beyond the preview
Go deeper on NCT01524341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01524341.